bioRxiv Science⌕ Search

bioRxiv · 10.1101/2022.08.31.506101

Artificial Intelligence based Liver Portal Tract Region Identification and Quantification with Transplant Biopsy Whole-Slide Images

Abstract

Liver fibrosis staging is clinically important for liver disease progression prediction. As the portal tract fibrotic quantity and size in a liver biopsy correlate with the fibrosis stage, an accurate analysis of portal tract regions is clinically critical. Manual annotations of portal tract regions, however, are time-consuming and subject to large inter- and intra-observer variability. To address such a challenge, we develop a Multiple Up-sampling and Spatial Attention guided UNet model (MUSA-UNet) to segment liver portal tract regions in whole-slide images of liver tissue slides. To enhance the segmentation performance, we propose to use depth-wise separable convolution, the spatial attention mechanism, the residual connection, and multiple up-sampling paths in the developed model. This study includes 53 histopathology whole slide images from patients who received liver transplantation. In total, 6,012 patches derived from 30 images are used for our deep learning model training and validation. The remaining 23 whole slide images are utilized for the model testing. The average liver portal tract segmentation performance of the developed MUSA-UNet is 0.94 (Precision), 0.85 (Recall), 0.89 (F1 Score), 0.89 (Accuracy), 0.80 (Jaccard Index), and 0.91 (Fowlkes-Mallows Index), respectively. The clinical Scheuer fibrosis stage presents a strong correlation with the resulting average portal tract fibrotic area (R=0.681, p<0.001) and portal tract percentage (R=0.335, p=0.02) computed from the MUSA-UNet segmentation results. In conclusion, our developed deep learning model MUSA-UNet can accurately segment portal tract regions from whole-slide images of liver tissue biopsies, presenting its promising potential to assist liver disease diagnosis in a computational manner.

Source connections

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Yu, H., Sharifai, N., Jiang, K., Wang, F., Teodoro, G., Farris, A. B., Kong, J.. 2022-09-03. Artificial Intelligence based Liver Portal Tract Region Identification and Quantification with Transplant Biopsy Whole-Slide Images. https://doi.org/10.1101/2022.08.31.506101

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

mFrag: Integrating External DNA Methylation References Improves Lung Cancer Early Detection by Fragmentomics

Fragmentomics analyzes features of circulating cell-free DNA fragments (e.g., fragment length or end motifs) derived from whole-genome sequencing of liquid biopsy samples (blood or other body fluids), enabling non-invasive early cancer detection. Here we present mFrag, a framework that integrates external methylation reference atlases with fragmentomic features for lung cancer detection. mFrag comprises two complementary methods: mFrag-Weight, which uses DNA methylation information to weight fragmentomic features, and mFrag-Net, which integrates fragmentomic features and external DNA methylation data through neural networks. We average the output probabilities of the two methods to obtain a final prediction score. The mFrag model was trained using 287 individuals at risk for lung cancer. In an independent case-control testing set comprising 385 non-cancer controls and 46 cancers (28 stage I, 12 stage II, and 6 stage III or IV), mFrag outperforms a DELFI-style fragmentomic approach, improving PR-AUC from 0.455 to 0.720 and sensitivity at 99% specificity from 0.043 to 0.478, with ROC-AUC from 0.871 to 0.908. For stage I lung cancer, mFrag raises PR-AUC from 0.314 to 0.558 and ROC-AUC from 0.855 to 0.894. Applied to end 4-mer motif features, mFrag likewise improved over an unweighted baseline, with gains contributed by both mFrag-Weight and mFrag-Net. In summary, mFrag improves the accuracy of fragmentomics-based lung cancer detection through integrating external DNA methylation data and the complementarity of its two component models, without incurring any additional data-generating cost.

bioinformatics↗

AOPTK: Open-Source Software for AI-Assisted Toxicological Literature Analysis

Motivation: Toxicologists today face a challenge: although vast amounts of data describing how chemicals affect human health are available across scientific publications and regulatory reports, much of this information remains underutilized because extracting and interpreting evidence across thousands of studies is impractical to perform manually. Recent advances in artificial intelligence (AI), particularly in large language models (LLMs), provide new opportunities to automate toxicological literature analysis. Results: Herein, we present the Adverse Outcome Pathway Toolkit (AOPTK), an open-source Python package for AI-enhanced analysis of toxicological and biomedical literature. AOPTK supports (i) automated literature retrieval from databases such as PubMed Central and Europe PMC, (ii) direct processing of full-text articles in PDF format, and (iii) LLM-assisted analysis tools to identify chemicals and extract their relationships to biological effects under user-defined conditions. We demonstrate its utilities through a case-study identifying potential non-genotoxic carcinogens based on their ability to inhibit gap junction intercellular communication (GJIC). The LLM-enhanced analysis achieves 81% agreement with an expert-curated inhibitor list and 95% accuracy in predicting inhibition versus no inhibition when analysing the same subset of 86 publications. Automated retrieval and analysis of 1 124 publications from PubMed Central further demonstrated the feasibility of applying AOPTK to large-scale literature analyses. Availability: The package is developed open source on GitHub, disseminated through PyPI and Bioconda and releases are archived on Zenodo. Individual tools are available in the Galaxy platform for accessible data analysis with user-friendly, findable, accessible, interoperable, and reusable (FAIR) and end-to-end workflows provided via WorkflowHub. The tools are available on usegalaxy.eu and usegalaxy.cz and are developed open source on GitHub.

bioinformatics↗

MELD: Mutation Effect Learning through Differential embeddings

We introduce MELD (Mutation Effect Learning through Differential Embeddings), a compact model for predicting the functional consequences of single nucleotide variants (SNVs) by training directly on the wild-type (WT) versus mutant differential. Interpreting SNVs is central to clinical genomics, yet experimental characterization cannot scale to millions of observed variants. Leading sequence-to-function models (Enformer, Borzoi, AlphaGenome) are trained on absolute genomic tracks and score variants post hoc through in-silico mutagenesis (ISM), so the WT-mutant difference never enters the training loss. MELD instead places the logit difference {Delta}z = zmut - zwt inside the supervised objective. It combines a shared CNN-Transformer encoder, a mutant-specific mutation-mask boost, multiscale mutation-centered pooling, and a learned adaptive amplification factor . On ClinVar (1.57M variants), MELD (1.9M parameters) reached an AUROC of 0.986 versus 0.800 for a same-data, same-backbone ISM baseline, with ablations confirming the contribution of each component. On a shared benchmark, it outperformed frozen foundation models with 3-1,300x more parameters (AUROC 0.967 vs. 0.924 for AlphaGenome and 0.936 for Nucleotide Transformer). With only 50, 000 training variants, it exceeded the ISM baseline trained on all 1.48M (AUROC 0.903 vs. 0.796) variants. On BRCA1 saturation genome editing, frozen MELD achieved a Spearman {rho} of 0.42, above Borzoi (0.40), and ClinVar transfer raised it to 0.45. These results demonstrate that direct differential supervision is a compact, data-efficient alternative to post-hoc ISM scoring with substantially larger pretrained models.

bioinformatics↗